аЯрЁБс>ўџ ўџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџ š ЭЩРсАСт\p Administrator BАa=œЏМ=?і'8X@"Зк1ШџArial1ШџArial1ШџArial1ШџArial1ШџArial1Ш<МArialрѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р рѕџ @ @ Р р @ @ Р р,ѕџ ј@ @ Р р*ѕџ ј@ @ Р р ѕџ ј@ @ Р р+ѕџ ј@ @ Р р)ѕџ@ @ Р рX@ @ Џ “€џ“€џ“€џ“€џ“€џ“€џ`…**лclinical_peptidesŒСС"Оќ ЊDRAVP_IDNameSequenceTarget_OrganismPubchemMolecular_FormulaDrugBank_Accession_NumberNCI_Thesaurus_CodeUNII CAS_NumberChembl Pubmed_IDComment DescriptionChemical_structure_depictionCondition_DiseaseTypeGroup Connectives DRAVPc042 Meplazumab Not Available SARS-CoV-2 405560467DB16465 0EL07E29VQ32307653##32291112No comments found.Meplazumab is an anti-CD147 antibody, which is a recepor on host cells for viruses such as SARS-CoV2. Meplazumab's inhibition of CD147 binding to the spike proteins of viruses is thought to inhibit their entry.It is investigated as an add-on therapy in patients with COVID-19 pneumonia.Structure not availableCOVID-19AntibodyInvestigationalAnti-SARS-CoV-2 DRAVPc043 Regdanvimabз>Regdanvimab light chain: ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS >Regdanvimab heavy chain: QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 434321767DB16405 I0BGE6P6I6 2444308-95-4 CHEMBL465046233319649##33436577Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate. Regdanvimab is indicated in the EU for the treatment of adult patients with COVID-19 who do not require supplemental oxygen and who are at risk of progressing to severe COVID-19.Phase a!clinical trial DRAVPc040 ZansecimabUSubunit 1 QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG Subunit 2 QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG Subunit 3 DIQMTQSPSSVSASVGDRVTITCKASQDVYIAVAWYQQKPGKAPKLLIYWASTRDTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYSSYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Subunit 4 DIQMTQSPSSVSASVGDRVTITCKASQDVYIAVAWYQQKPGKAPKLLIYWASTRDTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYSSYPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 434370480DB16389 A67ZN01CAW 2415205-37-5 CHEMBL465048630701027dZansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19). It is a humanized IgG4 isotype antibody that neutralizes phospho-Tie2 induction due to Ang2, thereby stopping angiogenesis. The mechanism behind the neutralization is due to the antibody binding with high affinity to, and inhibiting Ang2. DRAVPc041 AvdoralimabaSubunit 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV< SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG Subunit 2 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG Subunit 3 EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Subunit 4 EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 402425685DB16392 DW4CE8MKS9 2226393-85-5 CHEMBL4594463Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection). DRAVPc039 AstegolimabUSubunit 1 EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Subunit 2 EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Subunit 3 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Subunit 4 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 402425721DB16386 27TW751DTH 2173054-79-8 CHEMBL4594385ТAstegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia). DRAVPc037Gontivimab(ALX0171)ЂSubunit 1 DVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSSRSV 402425649DB16179 DY8W536BUY 1257358-38-5 CHEMBL4297692нGontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).=Respiratory Syncytial Virus Lower Respiratory Tract InfectionAnti-RSV DRAVPc038 AnsuvimabYSubunit 1 EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH< KPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Subunit 2 EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Subunit 3 DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Subunit 4 DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECEBOV 433770931DB16385 TG8IQ19NG2 2375952-29-5 CHEMBL459438831909070##26917592##26917593$Ansuvimab, formerly mAb114, is a fully human IgG1 mAb derived from a survivor of the 1995 Kikwit EBOV outbreak 11 years after infection, which displays strong glycan-independent binding to a conserved region of the GP1,2 protein that is responsible for interacting with the host NPC1 protein to mediate EBOV endolysosomal escape, a key step in the EBOV lifecycle. Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.Zaire ebolavirus infectionApproved, Investigational Anti-EBOV DRAVPc036Gimsilumab(MORAB-022)]Subunit 1 EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVVHEALHNHYTQKSLSLSPGK Subunit 2 EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVVHEALHNHYTQKSLSLSPGK Subunit 3 EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Subunit 4 EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 381127889DB15280 8961SFA7R3 1648796-29-5 CHEMBL2109430JGimsilumab is under investigation in clinical trial and used for COVID-19. DRAVPc035 IbalizumabcSubunit 1 QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK Subunit 2 QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTK< VDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK Subunit 3 DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Subunit 4 DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECHIV 347911363DB12698 LT369U66CE 680188-33-4 CHEMBL174302914722894##15180541НIbalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes.This drug was approved in March 2018 for the management of treatment-resistant HIV, in October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration. HIV infectionApprovedAnti-HIV DRAVPc034Leronlimab(PRO 140)HIV,SARS-CoV-2 135308456DB05941 Y1J4NP8FF0 674782-26-4 CHEMBL210934320377413##11134270юLeronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.4 It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.HIV infection, COVID-19Phase b! clinical trialAnti-HIV,Anti-SARS-CoV-2 DRAVPc03331909070##31774950##30686586cAnsuvimab is a fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease. Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD. DRAVPc031Maftivimab(REGN-3479) 381609201C6368H9886N1706O2008S46DB15899 KOP95331M4 2135632-36-7 CHEMBL429818432080199##30333617##29860496NMaftivimab is part of a product containing three monoclonal IgG1К antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.Maftivimab is indicated in combination with Odesivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. INMAZEB"!, formerly referred to as REGN-EB3, combines the three humanized IgG1К mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB"! is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020. DRAVPc032Odesivimab(REGN-3471) 381608746C6506H10024N1720O2030S42DB15900 UY9LQ8P6HW 2135632-30-1 CHEMBL4298188OOdesivimab is part of a product containing three monoclonal IgG1К antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Odesivimab is indicated in combination with Maftivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. INMAZEB"!, formerly referred to as REGN-EB3, combines the three humanized IgG1К mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB"! is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020. DRAVPc030Atoltivimab(REGN-3470) 381609025C6448H9954N1726O20< 02S44DB15898 FJZ07Q63VY 2135632-29-8 CHEMBL4298183QAtoltivimab is part of a product containing three monoclonal IgG1К antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Atoltivimab is indicated in combination with Odesivimab and Maftivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. INMAZEB"!, formerly referred to as REGN-EB3, combines the three humanized IgG1К mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB"! is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020. DRAVPc029"Bamlanivimab(LY-3819253,LY-CoV555) 434370493C6498H10068N1732O2032S46DB15718 45I6OFJ8QH 2423943-37-5 CHEMBL465037933024963##33113295­Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. Bamlanivimab is a neutralizing IgG1К mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells. Under the EUA granted in February 2021, bamlanivimab is used in combination with etesevimab to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19.The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children. DRAVPc028 Tixagevimab 434370464C6488H10034N1746O2038S50DB16394 F0LZ415Z3B 2420564-02-732651581##34548634хTixagevimab is an extended half-life recombinant monoclonal IgG1К antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. It is not approved for any indication by the FDA. Tixagevimab, in combination with cilgavimab, was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for whom vaccination is not recommended. DRAVPc027Cilgavimab(AZD1061) 440964522C6626H10218N1750O2078S44DB16393 1KUR4BN70F 2420563-99-9ЪCilgavimab is an extended half-life recombinant monoclonal IgG1К antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. Cilgavimab is not approved for any indication by the FDA. Cilgavimab, in combination with tixagevimab, was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for whom vaccination is not recommended. The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442). EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,5 and was approved in Canada soon after, on April 14, 2022. DRAVPc025Human interferon beta EEIKQLQQFQKED 101632004 C72H115N19O26DB14999 V9GU1EM8SF 74899-71-1 CHEMBL2108510ЄHuman interferon beta is a polypeptide drug which could used in the treatment of COVID-19. Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS). It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity. DRAVPc025.pngProtein DRAVPc026 Palivizumab„VH region: QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSM< ITNWYFDVWGAGTTVTVSS46506637DB00110 DQ448MW7KS 188039-54-5 CHEMBL1201586ЌHumanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. It is a monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.,Severe Respiratory Syncytial Virus Infection DRAVPc023 Aldesleukin…MPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFSQSIISTLT46508054C690H1115N177O202S6DB00041 M89N0Q7EQR 110942-02-4 CHEMBL1201438ЏAldesleukin is a recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells. DRAVPc023.png DRAVPc024 Bulevirtide*TNLSVPNPLGFFPDPAFGANSNNPDWDFNPNKDHWPEANKVGHBV,HDV 381128209DB15248 WKM56H3TLB 2012558-47-1 CHEMBL429771122161394##32926353The N-terminal of Bulevirtide is tetradecanoylglycyl and C-terminal is amide. Bulevirtide is a drug for the treatment of chronic Hepatitis D infection in adults with compensated liver disease.Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.Chronic Hepatitis D infectionPeptide Approved(HDV)Anti-HBV DRAVPc055 Nelfinavir64143 C32H45N3O4SDB00220C29285 HO3OGH5D7I 159989-64-7 CHEMBL5849397180##36466430##333725748Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. HIV InfectionSynthetic peptide DRAVPc022Albinterferon Alfa-2BHCV 347910117C3796H5937N1015O1143S50DB05396 4DVS4AG4DF 472960-22-8 CHEMBL210784212388634ЗAlbumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. The drug was under investigation as an alternative to pegylated IFN-Б-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.,Chronic HCV infection, Chronic HBV infectionAnti-HCV DRAVPc021Interferon alfacon-1ЇMCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE46505985C860H1353N227O255S9DB00069 56588OP40D 118390-30-0 CHEMBL12015578836913ƒInterferon alfacon-1 is a recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections.Chronic HCV infection DRAVPc056 Remdesivir 121304016 C27H35N6O8PDB14761C152185 3QKI37EEHE< 1809249-37-3 CHEMBL406561632350436##35000553##36466430<Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola. Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated in vitro activity against the Arenaviridae, Flaviviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, and Coronaviridae viral families.Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.Peptide like Small molecule DRAVPc020Interferon beta-1bЅSYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRNSARS-CoV-2,HIV46504458C908H1408N246O253S6DB00068 TTD90R31WZ 145155-23-3 CHEMBL12015639890522ЋInterferon beta-1b is a form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms.Anti-SARS-CoV-2,Anti-HIV DRAVPc019Interferon beta-1aІMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN46504899C908H1408N246O252S7DB00060 XRO4566Q4R 145258-61-3 CHEMBL1201562lInterferon beta-1a is a form of recombinant human interferon which could used for the treatment of COVID-19. DRAVPc018Interferon gamma-1b’CYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQHCV,HIV46507194C761H1206N214O225S6DB00033 21K6M2I7AG 98059-61-1 CHEMBL120156416375755##14525967ІInterferon gamma-1b is a form of recombinant human interferon used to treat infections associated with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV).$Chronic HCV infection, HIV infectionAnti-HCV,Anti-HIV DRAVPc017Peginterferon alfa-2bЅCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKEHCV,HBV46506669DB00022 G8RGG88B68 215647-85-1 CHEMBL120156128497432##25585348DPeginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).It is approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with Ribavirin or other antiviral drugs. DRAVPc017.pngAnti-HCV,Anti-HBV DRAVPc015Interferon alfa-n1ЅCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE46506227DB00011 41697D4Z5C 74899-72-2 CHEMBL2108509БInterferon alfa-n1 is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. It consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. DRAVPc016Interferon alfa-n346508902DB00018 47BPR3V3MP CHEMBL210904710868311rInterferon alfa-n3 is a purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).HIV infections, SARS infection DRAVPc057 Glecaprevir66828839 C38H46F4N6O9SDB13879C170029 K6BUU8J72P 1365970-03-1 CHEMBL354536324282816##36466430hGlecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral<  RNA replication. In combination with [DB13878], glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. Glecaprevir is available as an oral combination therapy with [DB13878] under the brand name Mavyret. This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both. DRAVPc013 Atazanavir148192 C38H52N6O7DB01072C66872 QZU4H47A3S 198904-31-3 CHEMBL116332924827##19496633~Atazanavir is an aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety. Atazanavir is an antiretroviral protease inhibitor that is used in the therapy and prevention of human immunodeficiency virus (HIV-1) infection and the acquired immunodeficiency syndrome (AIDS). The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. DRAVPc013.pngPeptidomimetic DRAVPc058 Saquinavir441243 C38H50N6O5DB01232C29444 L3JE09KZ2F 127779-20-8 CHEMBL11436466430ћSaquinavir is an aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. It is a member of quinolines and a L-asparagine derivative. Saquinavir is an HIV-1 protease inhibitor used in combination with ritonavir and other antiretrovirals for the Treatment of human immunodeficiency virus-1(HIV-1). DRAVPc014Peginterferon alfa-2a46504860DB00008 Q46947FE7K 198153-51-4 CHEMBL1201560ЛPeginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C. Approved in 2002 by the FDA, Pegasys is indicated for the treatment of HCV with Ribavirin or other antiviral drugs DRAVPc059 Indinavir5362440 C36H47N5O4DB00224C74585 9MG78X43ZT 150378-17-9 CHEMBL115‹Indinavir is a N-(2-hydroxyethyl)piperazine, a piperazinecarboxamide and a dicarboxylic acid diamide. It is an antiretroviral protease inhibitor used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Indinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and mild elevations in indirect bilirubin concentration. Indinavir is a rare cause of clinically apparent, acute liver injury. In HBV or HCV coinfected patients, antiretroviral therapy with indinavir may result in an exacerbation of the underlying chronic hepatitis B or C.HIV infection. DRAVPc010 GolotimodXW6992140 C16H19N3O5DB05475C76497 637C487Y09 229305-39-9 CHEMBL210381234258744?X is a D-type glutamate with a gamma position on the side chainђGolotimod(SCV-07) is a novel synthetic dipeptide containing the amino acids D-glutamine and L-tryptophan, which is used to treat hepatitis C by oral administration. SCV-07 has shown efficacy in treating various viral and bacterial infections. DRAVPc010.png DRAVPc011Oglufanide(IM862, Glufanide)EW100094DB05779C76274 4RHY598T5U 38101-59-6 CHEMBL2111029gOglufanide is a synthetic dipeptide immunomodulator composed of L-glutamic acid and L-tryptophan joined by a peptide linkage and in development for the treatment of chronic hepatitis C viral infection. Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States<  before being acquired by Implicit Bioscience in 2005. Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection. DRAVPc011.png DRAVPc012 Telaprevir3010818 C36H53N7O6DB05521C81603 655M5O3W0U 402957-28-2 CHEMBL23181322180548##28497432њTelaprevir is an oligopeptide consisting of N-(pyrazin-2-ylcarbonyl)cyclohexylalanyl, 3-methylvalyl, octahydrocyclopenta[c]pyrrole-1-carboxy, and 3-amino-N-cyclopropyl-2-oxohexanamide residues joined in sequence. Telaprevir is an orally available peptidomimetic small molecule with activity against hepatitis C virus (HCV). Telaprivir is a selective protease inhibitor that targets the viral HCV NS3-4A serine protease and disrupts processing of viral proteins and formation of a viral replication complex. DRAVPc012.pngApproved, Withdrawn DRAVPc060 Ritonavir392622 C37H48N6O5S2DB00503C1609 O3J8G9O825 155213-67-5 CHEMBL16321501034##36466430№Ritonavir is an L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. It is an antiretroviral protease inhibitor that is widely used in combination with other protease inhibitors in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Ritonavir is used in combination with other drugs to treat coronavirus disease 2019 (COVID-19) in patients who are at risk for progressing into a severe form of the disease. DRAVPc009 ThymalfasinSDAAVDTSSEITTKDLKEKKEVVEEAENSARS-CoV-2,HBV16130571C129H215N33O55DB04900C1253 W0B22ISQ1C 62304-98-7 CHEMBL210397915482167##35434596‘A thymus hormone polypeptide found in thymosin fraction 5 (a crude thymus gland extract) but now produced by synthesis.Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression, and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients. DRAVPc009.pngHBV infection, HCV infectionAnti-SARS-CoV-2,Anti-HBV DRAVPc061 Sotrovimab 472422617DB16355C177059 1MTK0BPN8V 2423014-07-5 CHEMBL465052433907512##33319649ОSotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus.Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy. DRAVPc008Alisporivir(Debio-025) XaVVLAaLLVXHCV,SARS-CoV-211513676 C63H113N11O12DB12139C169774 VBP9099AA6 254435-95-5 CHEMBL165195632376613##21060866XThe first X stands for D-Aminobutyric acid.The second X stands for Beta-methyl-tyrosine.FAlisporivir is a non-immunosuppressive analogue of cyclosporine A and an inhibitor of cyclophilins, with potential antiviral activity. Upon oral administration, alisporivir targets and inhibits human host cyclophilins, thereby inhibiting hepatitis C virus (HCV) replication in hepatocytes. Alisporivir may also inhibit the replication of various coronaviruses. In addition, it may inhibit mitochondrial cyclophilin-D, which regulates mitochondrial permeability transition pore (mPTP) opening. This may prevent cell death and tissue damage. It has a role as an anticoronaviral agent. DRAVPc008.pngChronic HCV infection, COVID-19QPhase b! clinical trial(HCV i< nfection treatment), Phase a! clinical trial(COVID-19)Anti-HCV,Anti-SARS-CoV-2 DRAVPc007 Albuvirtide"WEEMDREINNYTXLIHELIEESQNQQEKNEQELL 134694278C204H306N54O72C179096 MG9PC54E43 1417179-66-8 CHEMBL429725732180205##341764256X is a 3-maleimimidropropionic acid(MPA) modification. Albuvirtide (ABT) belongs to the class of HIV-1 fusion inhibitors. It is a 3-maleimimidopropionic acid (MPA)-modified peptide derived from the C-terminal heptad repeat sequence of HIV-1 gp41. It binds to gp41, blocking HIV-1 from entering and infecting certain cells DRAVPc007.pngQPhase b! clinical trial(HCV infection treatment), Phase a! clinical trial(COVID-20) DRAVPc006Fibrin-derived peptideGHRPLDKKREEAPSLRPAPPPISGGGYRSARS-CoV-2,EboV16208062C133H216N44O38 88650-17-325534190##33844613—FX-06 is a fibrin-derived synthetic peptide used for treatment of vascular leak syndrome in Ebola virus disease, Phase 2 trials for COVID-19 treatment. DRAVPc006.pngPhase a! clinical trialAnti-SARS-CoV-2,Anti-EBOV DRAVPc005 Sifuvirtide$SWETWEREIENYTRQIYRILEESQEQQDRNERDLLE49769437C201H307N59O7123233535##22228771˜Sifuvirtide is a linear 36-amino acid residues anti-HIV peptide, which designed based on the 3D structure of the HIV-1 gp41 fusogenic core conformation. DRAVPc005.pngHIV Infections DRAVPc004Enfuvirtide(Fuzeon, DP178)$YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF16130199C204H301N51O64DB00109C2105 19OWO1T3ZE 159519-65-0 CHEMBL52507633438525##33844613ЙEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. By disrupting the HIV-1 molecular machinery during its final stage of fusion with the target cell, enfuvirtide limits the spread of further infection. DRAVPc004.png DRAVPc003Plitidepsin(Aplidine) Not availableC1689 Y76ID234HW 137219-37-5 CHEMBL45193022180548##22332992RPlitidepsin is a didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans. It has a role as a marine metabolite, an antineoplastic agent and an anticoronaviral agent. DRAVPc003.png DRAVPc002 Boceprevir10324367 C27H45N5O5DB08873C117292 89BT58KELH 394730-60-0 CHEMBL21839422975763##22506260pBoceprevir is a hepatitis C virus NS3/4A protease inhibitor used in combination with other medications to treat chronic hepatitis C genotype 1 infection. Initially approved for use in 2012, it was withdrawn in 2015 because of the availability of more effective and better tolerated all oral regimens of direct acting antiviral agents. Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b. DRAVPc002.pngApproved, Withdrawn DRAVPc062 BebtelovimabГ>Heavy Chain QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light Chain QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQW< KSHRSYSCQVTHEGSTVEKTVAPTECS SARS-COV-2 472424854DB16755C182122 8YL4SYR6CU 2578319-11-4 CHEMBL480221033972947лBebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. It binds to a portion of the SARS-CoV-2 spike (S) protein's receptor-binding domain, thereby preventing spike protein interaction with ACE2 and subsequent viral entry into host cells. Bebtelovimab is notable in that the epitope to which it binds appears infrequently mutated, making it a viable candidate for use in resistant SARS-CoV-2 strains (i.e. variants of concern, VOCs), including the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants. Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients. DRAVPc001 Brilacidin25023695 C40H50F6N14O6DB12997C169816 I1679X069H 1224095-98-0 CHEMBL221941335080027##35695877##33572467@Brilacidin is a synthetic, nonpeptidic, small molecule mimetic of defensin, a type of host defense proteins/peptides (HDPs) or antimicrobial peptides (AMPs), with potential antibacterial and antiviral activities. Upon administration, brilacidin selectively destabilizes bacterial and viral membrane integrity, which leads to their proteolysis and degradation. HDPs are part of the innate immune response and act as the first line of defense against foreign pathogens. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been shown to suppress defensins. DRAVPc001.png"small molecule mimetic of defensin DRAVPc044PUL-042(PAM2CSK4 acetate)XSKKKK 165411979C65H126N10O12SDB16474 L33ZW7BO91 574741-81-435356002##36569949yX is cysteine, where the side-chain mercaptan hydrogen on the Cys residue is replaced by 2, 3-di (palmitoyl oxyl) propyl.›Pam2 is a synthetic lipopeptide which acts as an agonist at TLR2 and TLR6. Actions at these receptors suggest that Pam2 has potential antiviral properties. DRAVPc044.png DRAVPc045 AviptadilHSDAVFTDNYTRLRKQMAVKKYLNSILN16132300C145H232N40O43SC171932 A67JUW790C 40077-57-4 CHEMBL210604134846667##36227034‰Aviptadil is a synthetic form of vasoactive intestinal polypeptide (VIP), with potential anti-cytokine, anti-inflammatory, and immune-regulatory activities. Upon administration, aviptadil mimics endogenous VIP. In the lungs, aviptadil may prevent N-Methyl-D-aspartic acid (NMDA)-induced caspase-3 activation, inhibits the production of certain pro-inflammatory mediators, such as interleukin-6 (IL-6) and tumor-necrosis factor-alpha (TNFa), and may protect the lungs against a cytokine storm and inflammation. As cytokines cause the air sacs of the lungs to fill with water, making the sacs impermeable to oxygen, aviptadil may protect against pulmonary edema, and restores the barrier function at the endothelial/alveolar interface. This may improve blood oxygenation, respiratory distress, and prevent lung injury. VIP is a naturally synthesized peptide hormone that is highly concentrated in the lungs. DRAVPc045.png DRAVPc046 SolnatideCGQRETPEGAEAKPWYC91864495DB12136C152387 17ZS80333G 259206-53-6 CHEMBL429788535379296NSolnatide has been used in trials studying the treatment of Acute Lung Injury. DRAVPc046.png!COVID-19 caused Acute Lung Injury DRAVPc047 MetenkefalinYGGFM443363 C27H35N5O7SDB12668C91011 9JEZ9OD3AS 58569-55-4 CHEMBL13786UMetenkefalin is a synthetic form of the naturally occurring, endogenous opioid peptide, metenkephalin, and agonist of the zeta- and delta-opioid receptor and, to a lesser extent the mu-opioid receptor, with potential analgesic, neuromodulatory, immunomodulatory, anti-inflammatory, antinociceptive/analgesic, antidepressant, and gastrointestinal (GI) motility modulating activities. It is an investigational endogenous opioid being studied for the treatment of COVID-19. Metenkefalin, along with tridecactide, are under investigation as an immunomodulatory therapy for moderate to severe COVID-19. DRAVPc047.png DRAVPc048 Hepalatide/GTNLSVPNPLGFFPDHQLDPAFGANSNNPDWDFNPNKDHWPEAN< QVGHBV 438788936 8WL68J66B9LHepalatide is used for the treatment of chronic hepatitis B virus infection. Chronic HBV infection DRAVPc049$Flufirvitide-3(free c-terminal acid)VEDTKIDLWSYNAELLInfluenza virus 134812039 C87H133N19O29 QOG7VHU2LU 156953-42-335853393FFlufirvitide-3 is used for the treatment of influenza virus infection. DRAVPc049.pngInfluenza virus infection DRAVPc050Adaptavir(Dapta)ASTTTNYTHIV, HBV184644 C35H56N10O15DB16290 J208V4ZMP2 106362-34-9 CHEMBL18127611530189##16002156?Adaptavir is under clinical for the treatment of HIV infection. DRAVPc050.png DRAVPc051 CSA0001(LL-37 antiviral peptide)%LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 155907172C205H340N60O536LL-37 is under clinical for the treatment of COVID-19. DRAVPc052Angiotensin (1-7)(TXA127)DRVYIHP123805  C41H62N12O11DB11720C68962 IJ3FUK8MOF 51833-78-4 CHEMBL354534736579082##36453502ЖTherapeutic Angiotensin-(1-7) is a synthetic heptapeptide identical to endogenous angiotensin-(1-7) with vasodilator and antiproliferative activities. In the renin-angiotensin system, the vasodilating activity of angiotensin- (1-7), hydrolysed from angiotensin II by the type I transmembrane metallopeptidase and carboxypeptidase angiotensin converting enzyme 2 (ACE2) in vivo, counteracts the vasoconstricting activity of angiotensin II. DRAVPc052.png DRAVPc053Angiotensin IIDRVYIHPF172198 C50H71N13O12DB11842C173802 M089EFU921 4474-91-3 CHEMBL40840336584778##36378226ТAngiotensin II is a peptide hormone of the RAAS system used to raise blood pressure in septic or other forms of shock. As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. It is under investigation in clinical trial for the treatment of COVID-19. DRAVPc053.png DRAVPc054Compstatin 40(AMY-101)YICVXQDWGAHRCI 131634231C83H117N23O18S2DB14803C173801 4Z4DFR9BX7 1427001-89-5 CHEMBL429726035977025##32759504-X is Trp(Me), a methylated form of tryptophanC3 Complement Inhibitor AMY-101 is a compstatin-based inhibitor of human complement component C3, with potential use as a treatment for various diseases in which excessive complement activation plays a key role, including paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 glomerulopathy (C3G). Upon administration, C3 complement inhibitor AMY-101 selectively binds to C3 and inhibits C3 activity. This prevents complement pathway activation, and inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. C3 is a crucial and central component of the complement system, and the complement system is an integral component of the innate immune response. DRAVPc054.png DRAVPc063 Casirivimab 472422356DB15941C177087 J0FI6WE1QN 2415933-42-3 CHEMBL465024832540901##328078604Casirivimab is a monoclonal antibody combined with Imdevimab in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only. In November 2021, the same indication was approved by the EMA. DRAVPc064 Imdevimab 472422363DB15940C177063 2Z3DQD2JHM 2415933-40-1 CHEMBL465024932540904##325409015Imdevimab is a monoclonal antibody combined with casirivimab in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19. On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human Ig< G1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only. In November 2021, the same indication was approved by the EMA. DRAVPc065 Ombitasvir54767916 C50H67N7O8DB09296C123878 EQE3I70J3W  1258226-87-7 CHEMBL3127326G27179128## 24400777##27401997##28497432## 15302943## 25585348## 9305675No comments found. ЖOmbitasvir (ABT-267) is an antiviral drug for the treatment of hepatitis C virus (HCV) infection. Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, has favorable pharmacokinetic characteristics and is active in the picomolar range against genotype 1 - 6. In 2015, it was approved by FDA for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1. DRAVPc065.png!Hepatitis C Virus (HCV) infectionpeptide DRAVPc066 LopinavirHIV-192727 C37H48N4O5DB01601 C2095 2494G1JF75 192725-17-0 CHEMBL72989884314##19108994##9835517##30346663##22762019##21953914jLopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity.Like many other protease inhibitors (e.g. saquinavir, nelfinavir), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the HIV-1 protease. DRAVPc066.png-human immunodeficiency virus (HIV) infection.peptidomimetic DRAVPc067 NirsevimabЙ>Heavy_chain QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLEGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK >Light_chain DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECC6494H10060N1708O2050S46DB16258C170224 VRN8S9CW5V 1989556-22-0wu235544094##35235726## 32726528## 26641933##29373476ЫNirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG18) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants. Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.Arespiratory syncytial virus (RSV) lower respiratory tract diseaseantibody DRAVPc068 Grazoprevir44603531 C38H50N6O9SDB11575C166768 8YE81R1X1J 1350514-68-9 CHEMBL2063090425585348## 28497432## 22615282## 24900473## 24666106лGrazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Grazoprevir as first line therapy in combination with Elbasvir for genotypes 1a, 1b, and 4 of Hepatitis C. DRAVPc068.pnghepatitis C virus infections.Cyclic peptidomimetic DRAVPc069 Asunaprevir< Hepatitis C virus genotype 1b16076883 C35H46ClN5O9SDB11586 C114982 S9X0KRJ00S 630420-16-5 CHEMBL210573525061308 ## 22508297## 22256805ЋAsunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017. DRAVPc069.pnghepatitis C genotype 1b$Approved, Investigational, Withdrawn DRAVPc070 Voxilaprevir89921642 C40H52F4N6O9SDB12026C152922 0570F37359 1535212-07-7 CHEMBL447485523463199##28564569ъVoxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).Voxilaprevir has been available since July 2017 in a fixed dose combination product with sofosbuvir and velpatasvir as the commercially available product Vosevi. Vosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection. DRAVPc070.pngHepatitis C infections DRAVPc071 EtesevimabDB15897C173977 N7Q9NLF11I 2423948-94-9D Etesevimab is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.Under the EUA granted in February 2021, etesevimab is used in combination with bamlanivimab to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19:this EUA later expanded in December 2021 to include all younger children at high risk, including newborns. The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children. DRAVPc072 Tocilizumabж>Tocilizumab light chain: DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPS RFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT >Tocilizumab heavy chain: QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTY NPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPG LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC  347910344C6428H9976N1720O2018S42DB06273C84217 I031V2H011 375823-41-9 CHEMBL1237022027599663##25190079##20608753##12669473##32278585Р Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.It was approved by Health Canada on 30 April 2010.11 After being investigated to treat severely ill patients with COVID-19,1,7,8 tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. DRAVPc073 nirmatrelvir 155903259 C23H32F3N5O4DB16691 C182119 7R9A5P7H32 2628280-40-8 CHEMBL4802135 33460213##27799534##33098476=Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CLPRO) inhibitor that is the subject of clinical trial NCT04756531.In December 2021, the FDA granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and ritonavir, for the treatment of certain patients with mild-to-moderate COVID-19.Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 and later granted conditional marketing authorization by the European Commission on January 27, 2022. DRAVPc074 simeprevir  24873435  C38H47N5O7S2DB06290C129015 9WS5RD66HZ 923604-59-5 CHEMBL501849?25585348## <ї20166108## 26694454## 25206310## 24920913## 18678486ДSimeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. Simeprevir was approved by the FDA in November 2014 and is marketed under the brand name Olysio as oral tablets. Administered once daily with food, 150mg simeprevir capsule is used in combination with Sofosbuvir in patients with HCV genotype 1 without cirrhosis . DRAVPc075 glecaprevir C170029  K6BUU8J72P24282816=Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. Glecaprevir is available as an oral combination therapy with Pibrentasvir under the brand name Mavyret. This fixed-dose combination therapy was FDA-approved in August 2017. DRAVPc076 voxilaprevir C40H52F4N6O9S CHEMBL4474855 23463199 ## 28564569m Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Voxilaprevir has been available since July 2017 in a fixed dose combination product with sofosbuvir and velpatasvir as the commercially available product Vosevi. Approved, Investigational DRAVPc077 daclatasvir  25154714 C40H50N8O6DB09102 C114981 LI2427F9CI 1009119-64-5 CHEMBL2023898J 27029743## 25585348## 25046163## 24204123## 26486762## 23431163##24521299eDaclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg Sofosbuvir for genotype 1a/b patients with or without cirrhosis as second-line therapy. DRAVPc078 sofosbuvir45375808 C22H29FN3O9PDB08934 C101263 WJ6CA3ZU8B 1190307-88-0 CHEMBL1259059Œ 26426038## 27482432## 9305675## 28248189## 23262999## 26196665## 25585348## 28497432## 15483230## 25659285## 24733478## 24289735 20801890##7Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).Since 2014, sofosbuvir has been available as a fixed dose combination product with Ledipasvir (tradename Harvoni) used for the treatment of chronic Hepatitis C. Approved in October 2014 by the FDA, Harvoni is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without Ribavirin depending on the level of liver damage or cirrhosis Label.џ š ЭЩР   dќЉёвMbP?_*+‚€%џСƒ„Ё"dр?р?UOџџџџџџџџџ џ џ џ џ џџџџџџџџџџџџџџџџџџџ џ!џ"џ#џ$џ%џ&џ'џ(џ)џ*џ+џ,џ-џ.џ/џ0џ1џ2џ3џ4џ5џ6џ7џ8џ9џ:џ;џ<џ=џ>џ?џ@џAџBџCџDџEџFџGџHџIџJџKџLџMџNџ§ § § § § § § § § §  §  §  §  §  § § § § § § § § § § § § § § §  §  §  §  §  § § § §  § !§ "§ #§ $§ § %§ § &§ § '§  (§  )§  *§  §  +§ § § § ,§ !§ -§ .§ /§ § 0§ § 1§ § 2§  3§  4§  5§  §  6§ § § § ,§ !§ 7§ 8§ 9§ § :§ § ;§ § <§  =§  >§  §  §  ?§ § § § ,§ !§ @§ A§ B§ § C§ § D§ § E§  F§  G§  §  §  H§ § § § ,§ !§ I§ J§ K§ L§ M§ § N§ § O§  P§  Q§  §  §  R§ § S§ § ,§ T§ U§ V§ W§ X§ Y§ § Z§ § [§  \§  ]§  ^§  §  _§ § `§ § a§ b§ c§ d§ e§ § f§ § g§ § h§  i§  j§  §  §  k§ § § § ,§ !§ l§ m§ n§ o§ p§ § q§ § r§ s§ t§ u§ § v§ § w§ § x§ y§ z§ {§ § |§ }§ § ~§ § § €§ § ‚§ § ƒ§ § „§ § …§ †§ ‡§ V§ W§ X§ Y§ § Z§ § [§ \§ ]§ ˆ§ § ‰§ § `§ § x§ b§ Š§ ‹§ § X§ Œ§ § Ž§ § § § ‘§ ’§ § “§ § `§ § x§ b§ ”§ •§ § X§ –§ —§ ˜§ § ™§ š§ ›§ ’§ § œ§ § `§ § x§ b§ § ž§ § X§ Ÿ§  § Ё§ § Ђ§  Ѓ§  Є§  ’§  §  Ѕ§ § `§ § x§ b§ І§ Ї§ § § Ј§ Љ§ Њ§ § Ћ§  Ќ§  ­§  Ў§  §  Џ§ § § § x§ !§ А§ Б§ § § В§ Г§ Д§ § Е§  Ж§  §  З§  §  И§ § § § x§ !§ Й§ К§ § § Л§ М§ Н§ § О§  П§  §  З§  §  Р§ § § § x§ !§ С§ Т§ У§ Ф§ Х§ Ц§ § Ч§  Ш§  Щ§  §  §  Ъ§ Ы§ § Ь§ x§ Э§ Ю§ Я§ L§ а§ § б§ § в§  г§  д§  §  §  е§ ж§ § x§ T§ з§ и§ й§ o§ к§ л§ м§ § н§  о§  п§  §  §  р§ с§ „§ Ь§ x§ y§ т§ у§ ф§ х§ ц§ § ч§ § ш§  щ§  ъ§  ы§  §  ь§ э§ ю§ я§ №§ ё§ ђ§ § o§ ѓ§ є§ ѕ§ і§ ї§  ј§  љ§  њ§  §  ћ§ ќ§ §§ x§ y§ ў§ џ§ § § § § § § §  §  §  §  §  §  § Ь§ …§  §  §  §  § § § § § § §  §  §  §  §  § § § Ь§ x§  § § § § § § § § §  §  §   §  §  !§ § "§ x§ !§ #§ $§ %§ &§ '§ (§ )§ § *§  +§  ,§  -§  §  .§ „§ Ь§ x§ /§ 0§ 1§ 2§ § 3§ 4§ 5§ § 6§  7§  8§  §  §  9§ § Ь§ x§ !§ :§ ;§ <§ =§ >§ ?§ @§ § A§  B§  C§  D§  §  E§ F§ Ь§ x§ G§ H§ I§ J§ K§ L§ § M§ § N§  O§  P§  Q§  §  R§ S§ § Ь§ x§ T§ U§ V§ W§ o§ X§ § Y§ § Z§  [§  \§  §  §  ]§ § w§ Ь§ ,§ y§ ^§ _§ W§ `§ § a§ § b§  §  c§  d§  §  e§ § f§ Ь§ x§ g§ h§ § i§ j§ k§ l§ m§ n§ o§ p§ § q§ § "§ x§  § !r§ !s§ !§ !o§ !t§ !u§ !v§ !w§ !x§ ! y§ ! z§ ! {§ ! § ! |§ !}§ !w§ !~§ !x§ !y§ "§ "€§ "§ "§ "‚§ "ƒ§ "„§ "…§ " †§ " ‡§ " ˆ§ " § " ‰§ "w§ "~§ "x§ "y§ #Š§ #‹§ #J§ #§ #Œ§ #§ #§ #§ #Ž§ # § # § # Q§ # § # ‘§ #§ # § #Ь§ #x§ # § $’§ $“§ $§ $”§ $•§ $–§ $—§ $˜§ $ ™§ $ š§ $ ˆ§ $ § $ ›§ $œ§ $~§ $x§ $y§ %§ %ž§ %Ÿ§ %§ % § %Ё§ %Ђ§ %Ѓ§ %Є§ % Ѕ§ % І§ % Ї§ % Ј§ % Љ§ %Њ§ %§ %ю§ %,§ % § &Ћ§ &Ќ§ &­§ &§ &Ў§ &Ё§ &Џ§ &А§ &Б§ & В§ & Г§ & Ї§ & § & Д§ &Е§ &§ &ю§ &,§ & § 'Ж§ 'З§ '§ '§ 'И§ 'Й§ 'К§ 'Л§ 'М§ ' Н§ ' О§ ' П§ ' § ' Р§ 'С§ '§ '~§ 'Т§ ' § (У§ (Ф§ (§ (Х§ (Ц§ (Ч§ (Ш§ (Щ§ ( Ъ§ ( Ы§ ( Ь§ ( § ( Э§ (ќ§ (~§ (x§ (y§ )Ю§ )Я§ )а§ )б§ )в§ )г§ )д§ )е§ )ж§ ) з§ ) и§ ) й§ ) § ) к§ )л§ )м§ )ю§ )x§ )н§ *о§ *п§ *§ *р§ *§ *с§ *т§ *у§ * ф§ * х§ * ц§ * § * ч§ *§ *§ *x§ *!§ +ш§ +щ§ +ъ§ +ы§ +ь§ +э§ +ю§ +я§ +№§ + ё§ + ђ§ + ѓ§ + є§ + ѕ§ +і§ +ї§ +ю§ +ј§ +љ§ ,њ§ ,ћ§ ,ќ§ ,o§ ,§§ ,ў§ ,§ ,џ§ ,§ , § , § , § , § , § ,§ ,w§ ,ю§ ,§ ,y§ -§ - § - § - § - § - § -§ -§ -§ - § - § - § - § - § -§ -§ -ю§ -§ -§ .§ .§ .§ .o§ .§ .§ .§ .§ .§ . § . § . § . § . § .§ .§ .ю§ .…§ .y§ /§ /§ /§ /|§ / § /!§ /"§ /#§ /$§ / %§ / &§ / '§ / § / (§ /)§ /§ /ю§ /x§ /†§ 0*§ 0+§ 0,§ 0=§ 0И§ 0Й§ 0К§ 0-§ 0.§ 0 /§ 0 0§ 0 1§ 0 § 0 2§ 03§ 0§ 0ю§ 0…§ 0G§ 14§ 15§ 1§ 1=§ 16§ 17§ 18§ 19§ 1:§ 1 ;§ 1 <§ 1 =§ 1 § 1 >§ 1?§ 1§ 1~§ 1@§ 1G§ 2A§ 2B§ 2C§ 2D§ 2E§ 2§ 2F§ 2G§ 2H§ 2 I§ 2 J§ 2 K§ 2 § 2 L§ 2§ 2§ 2x§ 2!§ 3M§ 3N§ 3§ 3§ 3O§ 3P§ 3Q§ 3R§ 3S§ 3 T§ 3 U§ 3 V§ 3 § 3 W§ 3X§ 3§ 3Y§ 3§ 3!§ 4Z§ 4[§ 4\§ 4§ 4]§ 4^§ 4_§ 4§ 4`§ 4 a§ 4 § 4 b§ 4 c§ 4 d§ 4e§ 4§ 4ю§ 4!§ 5f§ 5g§ 5h§ 5§ 5i§ 5j§ 5_§ 5k§ 5l§ 5 m§ 5 n§ 5 o§ 5 § 5 p§ 5q§ 5§ 5ю§ 5…§ 5!§ 6r§ 6s§ 6t§ 6§ 6u§ 6§ 6v§ 6w§ 6x§ 6 y§ 6 z§ 6 {§ 6 § 6 |§ 6}§ 6~§ 6ю§ 6§ 6!§ 7§ 7€§ 7§ 7§ 7‚§ 7ƒ§ 7„§ 7…§ 7†§ 7 ‡§ 7 ˆ§ 7 § 7 § 7 ‰§ 7Š§ 7§ 7ю§ 7…§ 7!§ 8‹§ 8Œ§ 8§ 8Ž§ 8§ 8§ 8§ 8§ 8§ 8 § 8 § 8 § 8 § 8 ‘§ 8’§ 8“§ 8ю§ 8§ 9”§ 9•§ 9–§ 9—§ 9˜§ 9™§ 9§ 9§ 9š§ 9 ›§ 9 § 9 œ§ 9 § 9 § 9ž§ 9Ÿ§ 9ю§ : § :Ё§ :Ђ§ :Ѓ§ :Є§ :Ѕ§ :І§ :§ :Ї§ : Ј§ : Љ§ : Њ§ : § : Ћ§ :Ќ§ :w§ :ю§ :§ ;­§ ;Ў§ ;Џ§ ;§ ;А§ ;Б§ ;§ ;§ ;§ ; § ; § ; § ; § ; В§ ;§ ;ю§ <Г§ <Д§ <Е§ <§ <Ж§ <З§ <И§ <Й§ <К§ < Л§ < М§ < Н§ < § < О§ <П§ <§ <ю§ <§ =Р§ =С§ =Т§ =§ =У§ =Ф§ =Х§ =Ц§ =Ч§ = Ш§ = Щ§ = Ъ§ = § = Ы§ =Ь§ =§ =ю§ =x§ >Э§ >Ю§ >Я§ >§ >а§ >б§ >в§ >г§ >д§ > е§ > ж§ > з§ > и§ > й§ >к§ >§ >ю§ >§ ?л§ ?м§ ?§ ?н§ ?§ ?о§ ?п§ ?р§ ? с§ ? т§ ? у§ ? § ? ф§ ?§ ?§ ?x§ ?!§ @х§ @ц§ @§ @ч§ @§ @ш§ @щ§ @ъ§ @ ы§ @ ь§ @ э§ @ § @ ю§ @§ @§ @x§ @!§ Aя§ A№§ A§ A§ Aё§ Aђ§ Aѓ§ Aє§ Aѕ§ A і§ A ї§ A ј§ A љ§ A њ§ Aћ§ Aќ§ A§§ Aa§ A § Bў§ Bџ§ B§ B§ B§ B§ B§ B§ B§ B § B § B § B § B  § B § B § B § Bx§ By§ C § C§ C§ CL§ C,§ C§ C§ C§ C§ C § C § C § C § C § C§ C§ Ca§ CT§ D§ D§ D§ D§ D§ D§ D§ D§ D § D !§ D "§ D #§ D љ§ D $§ D%§ D&§ D'§ Dx§ D § E(§ E)§ E§ E*§ E+§ E,§ E-§ E.§ E/§ E 0§ E 1§ E 2§ E § E 3§ E4§ E5§ E§§ E6§ E § F7§ F8§ F§ F§ F9§ F:§ F;§ F<§ F=§ F >§ F ?§ F @§ F § F A§ FB§ FC§ F'§ Fa§ F § GD§ GE§ G§ G§ G,§ GF§ GG§ GH§ G I§ G љ§ G J§ G§ G§ G § G!§ HK§ HL§ HM§ H§ HN§ HO§ HP§ HQ§ HR§ H S§ H T§ H U§ H § H V§ H§ H§ Hx§ H!§ IW§ IX§ I§ I§ IY§ IZ§ I[§ I\§ I]§ I ^§ I _§ I `§ I § I a§ I§ I § Ia§ I!§ Jb§ Jc§ J§ J§ Jd§ Je§ Jf§ Jg§ Jh§ J i§ J j§ J k§ J љ§ J l§ J§ J'§ Jx§ J § Km§ Kn§ K§ K§ Ki§ Kj§ Kk§ Ko§ Kp§ K n§ K o§ K q§ K § K r§ K§ K'§ Ka§ K § Ls§ Lt§ L§ L§ L9§ Lu§ L;§ L<§ L=§ L >§ L v§ L w§ L § L x§ L§ L'§ Ly§ L § Mz§ M{§ M§ M§ M|§ M}§ M~§ M§ M€§ M § M ‚§ M ƒ§ M љ§ M „§ M§ M § Ma§ M § N…§ N†§ N§ N§ N‡§ Nˆ§ N‰§ NŠ§ N‹§ N Œ§ N § N Ž§ N § N § N§ N § Nx§ N >Ж@я7   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€‚ƒ„…†‡ˆ‰Š‹ŒŽ‘’“”•–—˜™š›œžŸ ЁЂЃЄЅІЇЈЉЊЋЌ­ЎЏАБВГДЕЖЗИЙКЛМНОПРСТУФХЦЧШЩЪЫЬЭЮЯабвгдежзийклмнопрстуфхцчшщъыьэюя№ёђѓєѕіїјљњћќ§ўџ     ўџџџ§џџџ§џџџ§џџџ§џџџ§џџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџRoot Entryџџџџџџџџpšс[пслўџџџWorkbookџџџџџџџџџџџџ–1